C-peptide in polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) is a common endocrine condition in women of reproductive age, characterized by irregular menstruation, hyperandrogenism, and the presence of ovarian cysts. The fundamental pathophysiology is intricate, encompassing insulin resistance, hyperinsulinemia, and impaired hormonal control. C-peptide, a consequence of insulin production, has emerged as a valuable biomarker for evaluating insulin resistance and beta-cell functionality in PCOS. Although previously deemed biologically inactive, current research indicates that C-peptide actively participates in cellular signaling, initiating pathways such as calcium-dependent signaling and endothelial nitric oxide synthase. Increased C-peptide levels in PCOS signify hyperinsulinemia and insulin resistance, which exacerbate the syndrome's metabolic and reproductive disorders. Clinical data substantiates the utilization of C-peptide as a diagnostic instrument, especially in assessing insulin resistance in non-obese PCOS patients, where conventional metrics such as body mass index (BMI) may be inapplicable. Nonetheless, obstacles persist in the standardization of C-peptide testing methodologies, and its interpretation may be affected by extrinsic factors like pharmaceutical interventions or concomitant conditions like obesity and diabetes. Individualized diagnostic methods are necessary due to the phenotypic variability of PCOS, which results in varying C-peptide levels among distinct subtypes. Future research must concentrate on enhancing diagnostic procedures, investigating the significance of C-peptide in the long-term management of PCOS, and elucidating its potential as a predictive biomarker for associated metabolic disorders. This review emphasizes the necessity for additional investigations of C-peptide in clinical practice to enhance diagnostic and therapeutic approaches for PCOS.